Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

WHO issues first emergency use validation for a Covid-19 vaccine

Chike OlisahbyChike Olisah
2 years ago
in Coronavirus
Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 

Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly

Share on FacebookShare on TwitterShare on Linkedin

The World Health Organization (WHO), on Thursday, issued its first emergency use validation for a Covid-19 vaccine, since the outbreak of the pandemic started about a year ago.

The United Nations Health agency listed the Comirnaty Covid-19 mRNA vaccine, produced by Pfizer/BioNTech, for emergency use, as it emphasized on its equitable distribution globally.

READ: COVID 19: Debt Service Suspension Initiative extended to June 2021 – World Bank

This disclosure is contained in a statement that was issued by WHO on Thursday, December 31, 2020, and can be seen on its website.

The statement says that WHO’s Emergency Use Listing (EUL) opens the door for countries to expedite their own regulatory approval processes to import and administer the vaccine. It also enables UNICEF and the Pan-American Health Organization to procure the vaccine for distribution to countries in need.

READ: European countries ban flights from UK as new Covid-19 strain spreads

What the WHO top official is saying

WHO Assistant Director-General for Access to Medicines and Health Products, Dr Mariangela Simao, said, “This is a very positive step towards ensuring global access to COVID-19 vaccines. But I want to emphasize the need for an even greater global effort to achieve enough vaccine supply to meet the needs of priority populations everywhere.

“WHO and our partners are working night and day to evaluate other vaccines that have reached safety and efficacy standards. We encourage even more developers to come forward for review and assessment. It’s vitally important that we secure the critical supply needed to serve all countries around the world and stem the pandemic.”

READ: FG suspends passports of 100 Nigerians for refusing post-arrival Covid-19 test

While reviewing the data on the Pfizer/BioNTech vaccine’s safety, efficacy and quality as part of a risk-versus-benefit analysis, regulatory experts convened by WHO from around the world and WHO’s own teams found that the vaccine met the must-have criteria for safety and efficacy set out by WHO and that the benefits of using the vaccine to address COVID-19 offset potential risks.

Meanwhile, the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) will convene on January 5, 2021, to formulate vaccine-specific policies and recommendations for this product’s use in populations, drawing from the SAGE population prioritization recommendations for COVID-19 vaccines in general, issued in September 2020.

READ: Covid-19: Russia applies to WHO for emergency use tag for its vaccine

The Comirnaty vaccine requires storage using an ultra-cold chain; it needs to be stored at -60°C to -90°C degrees. This requirement makes the vaccine more challenging to deploy in settings where ultra-cold chain equipment may not be available or reliably accessible. For that reason, WHO is working to support countries in assessing their delivery plans and preparing for use where possible.

READ: FG warns of significant increase in Covid-19 cases in January 2021

What you should know

It can be recalled that the Pfizer/BioNTech Covid-19 vaccine, which was certified 95% effective in the prevention of coronavirus disease in the final study, got approval for emergency use in the United States and the UK.

The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies and has the objective of making medicines, vaccines and diagnostics available as rapidly as possible to address the emergency while adhering to stringent criteria of safety, efficacy and quality.

READ: Covid-19: Nigeria is well into a Second Wave

The assessment looks at the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.

The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan. These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and plans for further studies.

READ: Covid-19: Europe launches mass vaccination of doses to end the pandemic

As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine.

Related

Tags: Covid-19World Health Organization WHO

Leave a Reply Cancel reply

HFM
Mega Millions
Mega Millions
Patricia





NM newsletters

Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

Recent News

  • Atiku asks CBN not to extend naira swap deadline, says vote buyers behind extension plot
  • FG reacts to allegations of anti-Tinubu elements in Aso Rock by Governor El-Rufai
  • NGX closes positive as investors gain N142 billion

Follow us on social media:

Recent News

Atiku asks CBN not to extend naira swap deadline, says vote buyers behind extension plot

Atiku asks CBN not to extend naira swap deadline, says vote buyers behind extension plot

February 1, 2023
FG reacts to allegations of anti-Tinubu elements in Aso Rock by Governor El-Rufai

FG reacts to allegations of anti-Tinubu elements in Aso Rock by Governor El-Rufai

February 1, 2023
  • Home
  • Exclusives
  • Markets
  • Industries
  • Economy
  • Business News
  • Financial Literacy
  • Lifestyle
  • Opinions

© 2023 Nairametrics

No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds

© 2023 Nairametrics